Stem Cell Therapy for Ankylosing Spondylitis

What This Article Covers

Ankylosing spondylitis (AS) is a chronic autoimmune form of inflammatory arthritis that primarily attacks the spine and sacroiliac joints, sometimes leading to fusion of the vertebrae over time. Because AS is driven by immune dysfunction, researchers have explored whether mesenchymal stem cells (MSCs) — with their immune-modulating properties — might calm the underlying inflammation. This article reviews what the early clinical and preclinical evidence actually shows, and where the science currently stands.

Standard treatment for AS includes NSAIDs, biologics such as TNF and IL-17 inhibitors, and physical therapy. For patients who don't respond well to these options, or who want to understand the research frontier, stem cell therapy has emerged as an experimental area of interest — though it remains investigational and is not an FDA-approved treatment for AS.

How It's Thought to Work

MSCs, whether derived from bone marrow, umbilical cord, or placental tissue, are known for their ability to secrete anti-inflammatory signaling molecules and to modulate T-cell activity. In AS, the theory is that infused MSCs could help shift the immune system away from the pro-inflammatory Th1/Th17 activity implicated in spinal inflammation and toward a more regulated, immune-tolerant state — potentially reducing inflammation in the sacroiliac joints and spine and slowing the abnormal new bone formation that causes vertebral fusion. This remains a biological hypothesis supported by lab and animal data rather than a fully proven clinical mechanism in humans.

What the Evidence Shows

The clearest human data comes from a 20-week open-label clinical trial published in Cell Transplantation, in which 31 patients with active AS who had failed NSAID therapy received four intravenous infusions of allogeneic mesenchymal stem cells over three weeks. The results were genuinely encouraging for an early-phase study: 77.4% of patients achieved an ASAS20 response (a standard measure of meaningful symptom improvement) by week four, disease activity scores (ASDAS-CRP) improved from 3.6 to 2.4, and MRI-detected spinal inflammation decreased significantly by week twenty — all with no adverse effects reported during the trial (Wang et al., Cell Transplantation, 2014). It's worth noting the benefit wasn't fully durable: the average response lasted about 7.1 weeks, and ASDAS-CRP scores drifted back up toward baseline by week twenty, suggesting repeat dosing would likely be needed to sustain any effect.

Preclinical work backs up the biological rationale. A 2023 study in Frontiers in Immunology found that human umbilical cord-derived MSCs, given intravenously to mice with induced spondylitis, shifted immune balance toward a less inflammatory state, lowered TNF-α and CCL-2 levels, and slowed both bone erosion and structural spinal lesions (Shen et al., Frontiers in Immunology, 2023). The authors were careful to note that this animal model captures inflammatory features of AS but not its genetic underpinnings, so results can't be assumed to translate directly to people.

A 2019 review in Biomedicine & Pharmacotherapy laid out the broader rationale for MSC therapy in AS (Ma et al., 2019). Separately, a case report published in Rheumatology in 2023 described a woman whose long-standing AS went into sustained remission — off all anti-TNF therapy — after she received a bone marrow transplant for unrelated leukemia, with disease activity and pain scores falling substantially (Bond & Sharma, Rheumatology, 2023). While this is a single case and not proof of a generalizable treatment effect, it's a notable real-world signal that reshaping the bone marrow/immune compartment can meaningfully affect AS activity. A registered Phase I/II trial of umbilical cord- and placenta-derived MSCs in AS (NCT01420432, Shandong University) was also designed to test this approach more formally.

Taken together, this is a small but real and genuinely promising body of evidence — not proof that stem cell therapy works for AS, but enough to justify continued, well-designed clinical study.

Who Might Be a Candidate

• Because MSC therapy for AS remains investigational, “candidacy” today applies mainly to clinical trial participation rather than routine treatment
• Adults with active AS confirmed by a rheumatologist, with an inadequate response to NSAIDs or biologics
• Those interested in enrolling in a registered clinical trial (searchable on ClinicalTrials.gov) rather than seeking treatment at a direct-to-consumer stem cell clinic
• Patients who understand that any benefit seen in early trials may be temporary and require repeat dosing

Anyone considering stem cell treatment for AS outside of a formal clinical trial should be aware that the FDA has issued repeated consumer warnings about unapproved regenerative medicine products, including stem cell and exosome offerings marketed directly to patients, due to reports of serious harm and lack of regulatory oversight (FDA Consumer Alert on Regenerative Medicine Products).

Bottom Line

Early research on mesenchymal stem cells for ankylosing spondylitis is genuinely encouraging — a small clinical trial showed strong short-term response rates and a good safety profile, and preclinical and case-report evidence support a plausible immune-modulating mechanism. But this is still early-stage science: the human trial was small, open-label, and showed benefits that faded over weeks rather than months, and no MSC-based product is FDA-approved for AS. Patients interested in this approach should discuss it with a rheumatologist and look toward legitimate, registered clinical trials rather than unregulated stem cell clinics.